Jeong Hwan Kim

Jeong Hwan Kim

Auto-generated profile, based on publicly available information

Jeong Hwan Kim

Department of Otorhinolaryngology-Head and Neck Surgery, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2023 in Korean Journal of Otorhinolaryngology-Head and Neck Surgery
Verified
Journal Article
Open access
PDF file
JYJun Yoo
Jun Yoo
JKJeong Hwan Kim
Jeong Hwan Kim
DPDong Hyun Park
Dong Hyun Park
SLSung Jin Lim
Sung Jin Lim
Min Young SeoMin Young Seo
Min Young Seo
SLSeung Hoon Lee
Seung Hoon Lee
Background and Objectives The aim of this study was to identify the frequency of indicators of National Health Insurance (NHI) coverage for positive airway pressure (PAP) therapy and to investigate the changes in patients receiving coverage for PAP therapy after the alterations were made in the insurance benefit standards for mild obstructive sleep apnea (OSA).Subjects and Method We divided the mild OSA patients into two groups according to altered categorization in insurance benefit standards (Mild1: 5≤AHI<10; Mild2: 10≤AHI<15). Eight indicators related to the NHI coverage were identified: four symptoms, three complications, and the minimal blood oxygen saturation during polysomnography (min SpO2) of ≤85% during polysomnography. We also investigated the change in the number of patients receiving insurance benefits under the altered insurance benefit standards.Results Of the 233 OSA patients, 66, 57, and 110 patients were diagnosed as mild, moderate and severe OSA, respectively. For all of them, the most common indicator related to NHI coverage for PAP therapy was the minimum SpO2 of less than 85% during polysomnography, and the second most common indicator was daytime sleepiness. In the mild OSA group, however, daytime sleepiness was found to be the most common indicator, found in 46 (70%) patients, followed by 38 (58%) patients with min SpO2 of less than 85%. In this group, 59 (89.4%) would have been benefited before the change in the insurance benefit standards whereas 51 patients (77.3%) would now be benefited under the changed insurance benefit standards.Conclusion Daytime sleepiness was the most commonly observed indicator in the mild OSA patients. The number of patients receiving insurance benefits for PAP therapy significantly decreased after the change was made in the NHI benefit standards for mild OSA

9 October 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
HLHyun Jee Lee
Hyun Jee Lee
JJJeong Yeon Ji
Jeong Yeon Ji
NCNayeon Choi
Nayeon Choi
JKJeonghwan Kim
Jeonghwan Kim
JPJung Je Park
Jung Je Park
SASoon-Hyun Ahn
Soon-Hyun Ahn
Background: The prognostic significance of p16/HPV discordance in oropharyngeal squamous cell carcinoma (OPSCC) remains incompletely characterized, particularly in Asian populations. We evaluated the prevalence and prognostic significance of p16/HPV discordance using the nationwide Korean Oropharyngeal Cancer (K-OPC) cohort.Methods: We retrospectively analyzed patients with OPSCC treated at 24 institutions in Korea between 2013 and 2022. Patients with available results for both p16 immunohistochemistry and HPV testing were classified into four subtypes: HPV-negative/p16-negative, HPV-negative/p16-positive, HPV-positive/p16-negative, and HPV-positive/p16-positive. Overall survival (OS) and disease-free survival (DFS) were compared using Kaplan-Meier analysis. Multivariable Cox regression for DFS was adjusted for age, sex, smoking status, alcohol consumption, primary tumor subsite, and tumor stage.Findings: Among 1,522 patients, 316 (20·8%) were HPV-negative/p16-negative, 193 (12·7%) were HPV-negative/p16-positive, 23 (1·5%) were HPV-positive/p16-negative, and 990 (65·0%) were HPV-positive/p16-positive, yielding an overall discordance rate of 14·2%. In multivariable analysis, the HPV-negative/p16-positive and HPV-positive/p16-positive groups had significantly better DFS than the HPV-negative/p16-negative group, whereas the HPV-positive/p16-negative group showed no significant difference from the HPV-negative/p16-negative group. In adjusted pairwise comparisons, DFS did not differ significantly according to HPV status among tumors with the same p16 status, whereas p16-positive tumors had significantly better DFS than p16-negative tumors within both HPV-negative and HPV-positive groups.Interpretation: In a nationwide Korean cohort, p16/HPV discordance occurred in 14·2% of OPSCC and was predominantly HPV-negative/p16-positive. Prognosis in discordant tumors tracked with p16 status rather than HPV status, independently of stage and other clinical covariates.

29 October 2026 in Biomedical Signal Processing and Control
Verified
Journal Article
Closed access
JKJeonghwan Kim
Jeonghwan Kim
YKYeongmin Kim
Yeongmin Kim
IJInyong Jeong
Inyong Jeong
TJTaewon Jung
Taewon Jung
GHGeesoo Hong
Geesoo Hong
HLHwamin Lee
Hwamin Lee

25 October 2026 in Korean Journal of Otorhinolaryngology-Head and Neck Surgery
Verified
Journal Article
Open access
PDF file
DTDorjsuren Tsagaankhuu
Dorjsuren Tsagaankhuu
JKJeonghwan Kim
Jeonghwan Kim
JCJung-Woo Choi
Jung-Woo Choi
SKSoon-Young Kwon
Soon-Young Kwon
Neuroendocrine carcinoma (NEC) of the head and neck is a rare and aggressive malignancy accounting for less than 1% of head and neck cancers. Its nonspecific presentation mimics squamous cell carcinoma, and immunohistochemistry is essential for diagnosis. We report two cases of NEC arising in the pharyngolaryngeal region. The first patient, a 50-year-old male, presented with oropharyngeal NEC with mixed small and large cell features and synchronous hepatic and pulmonary metastases; he was treated with palliative chemotherapy. The second, a 64-year-old male, had small cell NEC of the left aryepiglottic fold with a pulmonary nodule; he underwent CO2 laser-assisted supraglottic partial laryngectomy and pulmonary wedge resection, followed by chemotherapy and radiotherapy. Both cases were confirmed by synaptophysin and CD56 positivity. These cases underscore the need for accurate immunohistochemical diagnosis, comprehensive staging, and multidisciplinary treatment.

30 June 2022 in Journal of Clinical Otolaryngology
Verified
Journal Article
Open access
PDF file
JKJeong Hwan Kim
Jeong Hwan Kim
KOKyoung Ho Oh
Kyoung Ho Oh
SKSoon-Young Kwon
Soon-Young Kwon